Issue 15

PSYCHEDELICS INDUSTRY ACHIEVES INVESTMENT MILESTONE

Last week, the world’s first exchange-traded fund for psychedelic-drug companies launched in Toronto, as the investment industry aims to capitalise on rising interest in prospective mental health treatments using psychedelic medicines and therapies.

The Horizons Psychedelic Stock Index ETF, listed as PSYK, has been trading on the NEO Exchange.

BUSINESS AND INVESTMENT


Psychedelics-focused Mydecine Innovations Group files application to list on NASDAQ and receives conditional approval to list on NEO Exchange.


Cybin announces C$20 million bought-deal offering to fund clinical trials with psychedelics.


Awakn appoints James Collins, ex-Accenture strategy MD, as Chief Operating Officer.


Psyence Group Inc completes reverse takeover transaction and completes non-brokered financing.


Peter Tiel’s psychedelics-focused ATAI acquires majority stake in Recognify and its lead schizophrenia candidate.


MINDCURE announces pre- and post-psychedelic therapy adaptogen’ supplements.


Red Light Holland announces closing of C$9.77 million bought-deal financing.


Medical group Allied completes acquisition of Pacific Sun Funghi.


Field Trip Health Ltd. common shares to trade on the OTCQX Best Market.


Psychedelics start-up Alvarius raises €2.7 million to fund 5-MeO-DMT trials.


MindMed announces reorganisation of leadership.


CannaGlobal rebrands as GoodCap Wellness, focusing on psilocybin mushrooms.


NeonMind appoints Robert Tessarolo as President and Chief Executive Officer.


Pure Extracts lists on the OTC markets in the US.


Novamind looks to scale-up mental health clinics and clinical sites.


Havn Life announces deal to supply psychedelics for clinical trials to HealthTech Connex Inc.

Feature

EXPERTS WEIGH IN ON THE FUTURE OF THE PSYCHEDELICS INDUSTRY

During The PSYCH Symposium in November 2020, a panel of leading experts, operating in psychedelics sector discussed the advancement of research on psilocybin.

The groundbreaking, rapid progress being made in a number of regions across the US and beyond, the panel examined the realistic steps being taken towards the development of psychedelic treatment centres and how the business world is preparing for it.

REGULATION & LEGISLATION


Hawaiian Senate introduces bill to legalise the medical use of psilocybin.


Bill to legalise medical use of psilocybin, decriminalise certain plants & fungi introduced in Florida.


Oregon ballot measure comes into effect, decriminalising possession of LSD and psilocybin.


MDMA and psilocybin not approved for medicinal use in Australia under TGA interim ruling.


Plant Medicine Coalition formed to advocate for psychedelic medicines in the US.


Connecticut may establish task force to investigate psilocybin’s health benefits.

ACCESS A COMPREHENSIVE OVERVIEW OF PSYCHEDELICS

Psychedelic medicines are becoming increasingly mainstream around the world as a result of significant progress being made in clinical trials and public perception shifting in favour of new and innovative therapies.

This report contains:

  • Proprietary consumer insights on attitudes, uses and behaviours
  • Deep dives into the most transformative compounds and companies
  • Key regulations, transformative trends and commercial opportunities

RESEARCH & SCIENCE


PharmaTher signs agreement for microneedle delivery technology to deliver Ketamine.


Heroic Hearts Project UK launch short documentary that explores psychedelics as medicine with army veteran Guy Murray.


New study uncovers details of LSD’s effect on connectivity in the brain.


Study shows how LSD boosts sociability in mice.


First ketamine clinic for depression and addiction in UK to open in March.


Atai to work with Massachusetts Hospital to study psychedelics for mental health disorders.


Mindset advances set of psilocybin-inspired molecules to PoC stage of clinical trials.


Ongoing research investigates psilocybin to treat symptoms of dementia.